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Current Status of
Transcatheter Aortic Valve Replacement
John G. Webb, MD, David A. Wood, MD
Vancouver, British Columbia, Canada
Surgical aortic valve replacement (SAVR) has long been the mainstay of therapy for severe aortic stenosis. How-
ever, transcatheter aortic valve replacement (TAVR) is now generally accepted as the new standard of care for
patients with symptomatic aortic stenosis who are not candidates for open surgery. Arguably TAVR may also be
a preferred alternative to SAVR in carefully selected high-risk, but still operable, patients in whom morbidity and
mortality may be reduced. Although TAVR outcomes continue to improve, concerns remain with respect to vas-
cular injury, stroke, paravalvular regurgitation, and valve durability. However, it seems likely that with ongoing
refinement of transcatheter valve systems, techniques, and patient selection TAVR is becoming an increasingly
appealing option for a much broader range of patients. Randomized trials and ongoing surveillance will play an
important role as we enter a new era of rigorous clinical evaluation for minimally invasive therapies for struc-
tural heart disease. (J Am Coll Cardiol 2012;60:483–92) © 2012 by the American College of Cardiology
Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.01.071e
w
d
p
o
e
f
c
c
n
T
t
w
l
(
t
(
S
S
t
C
I
n
t
T
p
A
t
sWhen patients develop symptoms due to aortic stenosis,
functional limitation is inevitably followed by physical
deterioration, heart failure, and mortality. Aortic valve
replacement (AVR), specifically surgical AVR (SAVR),
improves symptoms and is generally accepted to prolong
survival on the basis of historical comparisons and long
experience (1). However, many symptomatic patients do not
undergo surgery, because they are not referred, are refused,
or are declined as candidates (1).
Since transcatheter AVR (TAVR) was first accomplished
just over a decade ago, clinical outcomes have steadily
improved (2). Recently TAVR became the only interven-
tion for aortic stenosis shown to prolong life in a random-
ized trial (3). Arguably TAVR is now the standard of care
for extremely high-risk or “inoperable” patients and is a
valid alternative to surgery for many high-risk but “opera-
ble” patients (4). As we pass 10 years of clinical experience
with TAVR and over 50,000 implants in over 40 countries,
a review of contemporary TAVR seems appropriate.
Transcatheter Valves
The SAPIEN valve. The current state-of-the-art Ed-
wards SAPIEN XT transcatheter heart valve (THV) (Ed-
ards Lifesciences Inc., Irvine, California) utilizes a balloon-
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2011, accepted January 2, 2012.xpandable cobalt chromium alloy tubular frame within
hich are sewn leaflets constructed from bovine pericar-
ium. The inflow of the frame is covered with fabric to
rovide an annular seal (Fig. 1).
For transarterial implantation the THV is compressed
nto a low-profile NovaFlex (Edwards Lifesciences) deliv-
ry catheter and introduced through a sheath placed in the
emoral artery. Alternatively a sheath can be placed surgi-
ally in the left ventricular apex or ascending aorta. In either
ase the THV is balloon-expanded within the diseased
ative valve displacing the diseased native leaflets (Fig. 2).
he low-profile (16-F to 19-F) SAPIEN XT/NovaFlex
ransfemoral system is in widespread clinical use around the
orld. However, availability in the United States remains
imited to patients enrolled in the randomized PARTNER-2
Placement of AoRTic TraNscathetER Valve-2) trial. At this
ime only the earlier generation RetroFlex transfemoral system
Edwards Lifesciences) is clinically available in the United
tates (Figs. 1 and 2). These systems utilize the earlier
APIENTHV, which requires the use of larger diameter 22-F
o 24-F sheaths.
oreValve. The CoreValve ReValving System (Medtronic
nc., Minneapolis, Minnesota) utilizes a self-expanding
itinol (a nickel-titanium alloy that is malleable at low
emperature, but relatively rigid at body temperature) frame.
he leaflets and annular seal are constructed of porcine
ericardium (Fig. 3). This THV is compressed within its
ccutrak delivery catheter (Medtronic) and introduced
hrough an 18-F sheath into the common femoral or
ubclavian artery. Once positioned within the diseased
ative valve the delivery catheter is withdrawn, releasing the
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is anchored within the aortic an-
nulus, but also extends superiorly
to anchor in the supracoronary
aorta.
Comparisons. These 2 valve
systems share more similarities
than differences (Table 1). Both
devices utilize similar low-profile
delivery systems, are compatible
with fully percutaneous access,
and can be implanted in a con-
ventional cardiac catheterization
laboratory with fluoroscopic guid-
ance alone under local anesthesia.
Only limited nonrandomized comparisons are available
(5,6). Deployment of the CoreValve device may be more
intuitive, and does not require rapid pacing, while deploy-
ment of the SAPIEN device may be more targeted. The
CoreValve device can, up to a point, be repositioned or
removed. However this process may not be benign (7).
Coronary obstruction may rarely occur with both THVs,
but may be more frequent with the SAPIEN type valves.
Atrioventricular block requiring pacemaker implantation is
more common with CoreValve. Currently, the SAPIEN
THV is supported by the randomized PARTNER (Place-
ment of AoRTic traNscathetER valve) studies (4). However
there is extensive experience with the CoreValve device and
similar rigorous evaluation is underway. Regardless of cur-
rent differences, both THV systems continue to evolve and
iterative improvements can be anticipated.
Newer valves. A number of newer transcatheter valves are
in early clinical evaluation. In general these incorporate
features, which reduce delivery catheter diameter, improve
Figure 1 Current Widely Available Transcatheter Valves
(A) The Edwards SAPIEN THV balloon-expandable valve (Edwards Lifesciences, Irvi
and a fabric sealing cuff. (B) The SAPIEN XT THV (Edwards Lifesciences) utilizes a
(C) The Medtronic CoreValve (Medtronic, Minneapolis, Minnesota) incorporates a
Abbreviations
and acronyms
AVR  aortic valve
replacement
MDCT  multidetector
computed tomography
SAVR  surgical aortic
valve replacement
STS  Society of Thoracic
Surgeons
TAVR  transcatheter
aortic valve replacement
THV  transcatheter heart
valveease of positioning and sealing, or facilitate repositioning or
removal (Fig. 4). For the most part these next generation
valves are constructed of self-expanding nitinol. Some valves
have unique expansion mechanisms: the Lotus valve (Bos-
ton Scientific Inc., Natick, Massachusetts) is designed to
expand laterally as longitudinal nitinol wires are retracted
and the Direct Flow valve (Direct Flow Medical Inc., Santa
Rosa, California) has a tubular fabric frame, which is
inflated with a rapid setting polymerizing agent. Self-
expandable systems offer the potential for recapture, repo-
sitioning, and removal if desired.
The Acurate (Symetis Inc., Ecublens, Switzerland) and
Portico (St. Jude Medical Inc., St. Paul, Minnesota) devices
extend from the annulus to the supracoronary aorta to assist
in coaxial alignment and fixation, as does CoreValve. The
Engager (Medtronic), JenaClip (JenaValve Inc., Munich,
Germany), and Acurate valves incorporate features that
facilitate positioning and anatomical orientation in relation
to the native valve commissures and coronaries. Other valves
incorporate new sealing mechanisms to reduce paravalvular
leaks.
Although these newer valves offer many desirable fea-
tures, there are concerns with respect to radial strength,
symmetric expansion, and late fracture with nitinol. Expe-
rience with newer leaflet technology is limited. Reposition-
able valves may be associated with aortic injury, atheroem-
bolism, or reduced durability. Whether clinical outcomes
will be equivalent or superior to currently available THVs
will need to be evaluated.
Patient evaluation. TAVR is technically feasible in most
patients with aortic stenosis. There are, however, several
necessary anatomic evaluations specific to TAVR. The
dimensions of the aortic annulus dimensions must be
evaluated noninvasively in order to select an appropriately
lifornia) incorporates a stainless steel frame, bovine pericardial leaflets,x
t chromium alloy frame and is compatible with lower profile delivery catheters.
pandable frame, porcine pericardial leaflets, and a pericardial seal.ne, Ca
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August 7, 2012:483–92 Transcatheter Aortic Valve Replacementsized valve. Transesophageal echocardiographic (8,9), mul-
tidetector computed tomography (MDCT), and magnetic
resonance imaging measurements are widely utilized (10–12).
rterial access is generally assessed with invasive angiogra-
hy or contrast MDCT. Most arteries are somewhat com-
liant and can accommodate sheaths slightly (1 to 2 mm)
arger than their internal diameter, although this may not be
he case when the artery is diffusely diseased, tortuous, or
alcified. The aorta should be evaluated with invasive
ngiography or contrast MDCT to assess technical issues
elated to the delivery and implantation of the specific valve
ype, aortic root and valvular calcification, and the risk of
oronary obstruction.
Whether TAVR is advisable depends not only on various
echnical considerations, but also on the likelihood of
unctional and survival benefit. Increasingly evaluation is
irected on identifying patients in whom a significant
mprovement in quality and duration of life is likely and
voiding unnecessary intervention in patients where the
Figure 2 Valve Delivery Catheters
(A, top) The RetroFlex 1 delivery system for the Edwards SAPIEN THV (Edwards Li
TraNscathetER Valve 1) trials (8 mm diameter). (A, Middle) The RetroFlex 3 syste
ter; Edwards Lifesciences). (B) The Accutrak delivery system with the Medtronic C
nesota). The prosthesis is enclosed within an outer sheath.
Figure 3 Fluoroscopic Images of Some Newer Valves Undergoin
The CENTERA valve (A) is self-expandable and utilizes an electronic motorized rele
tem and utilizes a 14-F expandable sheath (Edwards Lifesciences, Irvine, Californi
retrievable, and repositionable.procedure can be performed, but benefit is unlikely due to
advanced age and comorbidities. For this reason evaluation
of neurocognitive functioning, frailty, functional status,
mobility, and supports is increasingly being recognized as
important in patient selection.
Centers of expertise. Evaluation and management of
TAVR candidates is a complex process requiring the special
skills of interventional cardiologists with expertise in structural
heart disease, cardiac and vascular surgeons, anesthesiologists,
imaging specialists, and specialized nursing. This cooperative,
noncompetitive approach to dealing with this high-risk and
intensive procedure has been popularized as the multidisci-
plinary heart team. Ideally TAVR is best performed in a
specialized procedural suite able to utilize whatever percutane-
ous or open access techniques are necessary and to deal
appropriately with complications. The concept of a hybrid
room has been advocated; large enough to accommodate
sophisticated x-ray imaging, anesthesia, echocardiography, and
cardiopulmonary support (1).
ces, Irvine, California) as used in the PARTNER 1 (Placement of AoRTic
ards Lifesciences). (A, Bottom) The NovaFlex/SAPIEN XT system (6 mm diame-
ve (6 mm diameter, also with a tapered nosecone; Medtronic, Minneapolis, Min-
rly Evaluation in Patients
nd retrieval system, while the S3 valve (B) incorporates an improved sealing sys-
The Portico valve (St. Jude Medical Inc., St. Paul, Minnesota) is self-expandable,fescien
m (Edw
oreValg Ea
ase a
a). (C)
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Society of Thoracic Surgeons (STS) noted that proce-
dural risks are high, valve interventions are rarely emer-
gent, and that extensive support infrastructure and pro-
cedural volumes are necessary for optimal outcomes and
efficiencies. Restricting this new therapy to regional
centers of excellence was recommended (1). With well
over 1,000 cardiac surgical programs in the United States
with an average volume of 60 aortic cases per year, this
will undoubtedly be controversial.
Endovascular access. The femoral artery has been the
most popular access site. Although originally requiring a
surgical cutdown most experienced groups now utilize a
percutaneous puncture and suture pre-closure technique
avoiding the need for open surgical access (Fig. 5). Current
consensus, with some exceptions, strongly favors transfemo-
ral arterial access as the preferred, default approach for
TAVR.
Current transcatheter valve systems utilize vascular access
Comparison of the Edwards SAPIEN XTand Medtronic CoreValve ProsthesesTable 1 Comparison of the Edwards SAPIEN XTand Medtronic CoreValve Prostheses
Characteristics Edwards SAPIEN XT
Medtronic
CoreValve
Frame Cobalt chromium Nitinol
Leaflets Bovine pericardial Porcine pericardial
Seal Synthetic Porcine pericardial
Expansion Balloon expandable Self-expanding
Repositionable No Yes
Retrievable No Yes
Annular/valvular fixation Yes Yes
Ascending aorta fixation No Yes
Manufacturers diameter* 23, 26 mm 26, 29 mm
Treatable annulus diameter* 18–25 mm 20–27 mm
Length 15–17 mm 53–55 mm
Sheath internal diameter 18-F, 19-F 18-F
Sheath external diameter 7 mm 7 mm
Minimal arterial diameter 6 mm 6 mm
Suitable for
Aortic stenosis Yes Yes
Aortic regurgitation If calcific stenosis present If size appropriate
Dilated ascending aorta Yes No
Pulmonary position Yes No
Valve-in-valve All 4 valve positions Aortic only
Transapical access Yes No
Transaxillary access Yes, limited experience Yes
Transaortic access Yes Yes
Longest published follow-up 6 yrs 4 yrs
Pacemaker requirement 3%–8% 14%–40%
CE mark approval Yes (2007) Yes (2007)
FDA approval SAPIEN transfemoral only No
Randomized trial results PARTNER A and B Results anticipated
2013
*SAPIEN XT 20, 29 mm (Edwards Lifesciences, Irvine, California); and CoreValve 31 mm
(Medtronic, Minneapolis, Minnesota) devices are available in some countries.
CE Conformite Europeenne; FDA Food and Drug Administration; PARTNER Placement of
AoRTic TraNscathetER Valve Trial.sheaths, which are typically described in terms of their innerdiameter in French size (3  internal diameter in millime-
ters). Sheath external diameters are slightly larger. The only
approved device in the United States (SAPIEN valve)
requires a 22-F or 24-F sheath with outer diameters of just
over 8 or 9 mm, respectively. However, current generation
systems generally utilized outside the United States utilize
smaller sheaths (18-F with outer diameters of7 mm). A
relatively compliant nondiseased artery can generally accom-
modate a sheath slightly larger than its internal diameter. In
the absence of severe calcification, tortuosity, or atheroma
an arterial diameter 6 mm might be adequate for an 18-F
system, while an arterial diameter of 8 mm might be
required for a 24-F system. Assessing this minimal arterial
diameter is fundamental to patient selection.
However, many patients have small or diseased femoral
arteries. On occasion an open surgical retroperitoneal ap-
proach is utilized to gain access to the larger iliac artery in
patients with femoral disease. Recently, transaxillary (some-
times referred to as subclavian) access has gained popularity
as an alternative to femoral access, although a surgical
cutdown is generally utilized (6,13,14).
A transapical approach, with direct access to the left
ventricle through an intercostal thoracotomy, has several
potential advantages: a low risk of peripheral vascular
injury, a direct pathway to the aortic valve, and easier
antegrade crossing of the diseased aortic valve. Concerns
relate to direct myocardial injury, bleeding, mitral injury,
hemodynamic instability, and post-operative respiratory
compromise and thoracotomy pain. The transapical pro-
cedure is generally associated with the Edwards SAPIEN
valve, although a number of newer valves (e.g., JenaClip,
Engager, Portico, Acurate) have been developed for this
application.
Most recently, a transaortic approach with direct access to
the ascending aorta has been advocated. Although requiring
a mini-thoracotomy and aortotomy, potential advantages
over the transapical approach include a reduced risk of
myocardial injury and bleeding and an access route more
familiar to cardiac surgeons.
Valve Function
In vitro testing generally suggests performance equivalent or
superior to surgically implanted valves, in part due to the
absence of a bulky sewing ring. Large clinical registries
routinely report mean transaortic systolic gradients of
around10 mmHg and an orifice area ranging between 1.2
and 1.9 cm2, depending on prosthesis size and type (2). The
only randomized comparison of TAVR and SAVR (the
699-patient PARTNER 1A trial) documented superior
hemodynamic function with the SAPIEN valve (mean
gradient 10.2  4.3 mm Hg vs. 11.5  5.4 mm Hg, p 
0.008; mean orifice area 1.59  0.48 cm2 vs. 1.44  0.47
cm2, p 0.002 at 1 year) (3). As with SAVR, relief of aortic
stenosis with TAVR is associated with favorable effects on
left ventricular mass, volumes, and function. Left ventricular
487JACC Vol. 60, No. 6, 2012 Webb and Wood
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and may continue to improve with time, particularly in the
absence of infarction (15).
Aortic regurgitation. Significant transvalvular regurgita-
tion is rare after transcatheter AVR (3). However, paraval-
vular regurgitation, due to incomplete annular sealing, is
Figure 4 Valves Undergoing Early Evaluation
(A) Lotus (Boston Scientific Inc., Natick, Massachusetts), (B) Direct Flow (Direct F
(D) Portico (St. Jude Medical Inc., St. Paul, Minnesota), (E) Engager (Medtronic In
(G) Acurate valve (Symetis Inc., Ecublens, Switzerland), and (H) Inovare (Braile Bio
Figure 5 Percutaneous Access and Closure
(A) The femoral artery is punctured and a guidewire placed within the artery. Percu
(B) The large vascular access sheath is inserted. (C) Following sheath removal thcommon. Paravalvular leaks may occur due to prosthesis
undersizing or incomplete expansion, or due to implanta-
tion of a prosthesis too high or too low such that the sealing
cuff is not apposed to annular tissue.
Core lab echocardiographic evaluation in the PARTNER
trials documented greater than or equal to moderate para-
edical Inc., Santa Rosa, California), (C) HLT (Bracco Inc., Princeton, New Jersey),
neapolis Minnesota), (F) JenaClip (JenaValve Inc., Munich, Germany),
a Inc., São José do Rio Preto, Brazil) valves.
us sutures are placed using a “pre-closure” device.
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inoperable patients and 12.2% of operable patients (3,4).
However, net aortic regurgitation (both valvular and para-
valvular combined) was actually reduced after TAVR
(3,4,9,13).
Severe paravalvular regurgitation may result in severe
hemodynamic consequences, although improved implanta-
tion techniques and more accurate annulus sizing have made
such severe leaks increasingly less common. Most leaks are,
in fact, mild to moderate, well tolerated, not associated with
hemolysis, and do not worsen with time (13,14). Neverthe-
less, it is clear that moderate and even mild leaks are
associated with a less favorable late survival than no leak
(16,17). Whether this association represents cause and effect
is unknown. When paravalvular regurgitation is excessive
redilation, repositioning, or implantation of a second, over-
lapping transcatheter valve can often reduce or correct the
problem (13,18). However, these interventions may be
associated with a poorly understood increased risk of em-
bolic stroke and should not be taken too lightly (7,19).
Valve durability. Clinical and echocardiographic follow-up
of both the SAPIEN and CoreValve prostheses beyond 3
and up to 5 years has been well documented (15–17,20). To
date, late leaflet failure has been exceedingly rare and in
vitro accelerated wear testing is consistent with durability
comparable to surgical bioprostheses. Mid term durability of
the SAPIEN and CoreValve frames has been documented and
frame fracture has not been observed. However, only time will
tell if durability matches that of surgical bioprostheses.
Clinical Outcomes
Survival. Contemporary registry series routinely document
rocedural success (defined loosely here as implantation of a
unctional valve with the patient surviving the procedure) in
ver 95% and procedural survival (30 days) in over 90% of
igh-risk patients (2,5,18,21). More rigorous assessments
re now available from the randomized PARTNER trials.
As the first of 2 parallel trials completed, PARTNER 1B
andomized 358 “inoperable” patients (in whom surgical
isk was prohibitive as judged by experienced surgeons) to
ither transarterial (femoral artery access) TAVR or best
edical management (Fig. 6) (4). Despite early generation
large-diameter systems and minimal operator experience
with TAVR, the 30-day mortality of 6.4% among patients
assigned to TAVR compared very favorably with the STS
mortality estimate of 11.6% with surgery. By way of
comparison, the STS National Cardiac Database reports
that among patients (low- and high-risk combined) actually
undergoing SAVR in the United States, mortality was
similarly 6.4%. Patients managed medically had a mortality
exceeding 50% at 1 year. The PARTNER 1B trial docu-
mented a dramatic 20% absolute reduction in mortality at 1
year with transarterial TAVR, meeting statistical tests for
superiority. At 2 years the survival curves continue todiverge with an additional 16.9% difference in mortality
accruing between 1 and 2 years (16).
The parallel trial, PARTNER 1A, was completed a year
later (Fig. 7) (3). In this trial 699 high-risk patients were
randomized to either TAVR (either a transfemoral or
transapical as determined by access considerations) or
SAVR. The mean STS score was just under 12%, repre-
senting the top 5% of patients in terms of operative risk.
Mortality at 30 days was actually lower with TAVR than
SAVR (3.4% vs. 6.5%, p  0.07) and at 1 year (24.2% vs.
26.8%, p  0.44); not statistically significant, but still
meeting tests for noninferiority.
In addition to the previous intention-to-treat analysis
(treatment assigned, 30 days from randomization), the
as-treated analysis (treatment received, 30 days from the
procedure) has assumed relevance as surgical patients
were less likely to undergo their assigned procedure
within 30 days, thereby reducing procedural deaths
within 30 days of randomization. In the as-treated
analysis femoral transarterial TAVR 30-day mortality
was less than one half that with SAVR (3.7% vs. 8.2%,
p  0.05). As in previous observational studies of TAVR,
mortality was higher among patients that underwent a
transapical procedure. The transapical procedure did not,
on its own, meet the test of noninferiority. To what
degree this difference is attributable to selection of
higher-risk patients and a learning curve in the transapi-
cal group is controversial.
Functional benefit. For many elderly patients morbidity
may be a greater concern than mortality. A marked and
durable improvement in functional class and quality of life
after TAVR has been well documented (15,22,23). The
randomized PARTNER trials documented a marked re-
duction in rehospitalization with transfemoral TAVR as
compared with medical management and, in comparison
with surgery, a significantly shorter length of stay as well as
earlier improvement in functional status (3,4,22).
Late survival. Registries report survival 1 year following
TAVR ranging from 69% to 85% (3–5,15,18,21). Similarly,
1-year survival in the PARTNER trials following TAVR
was 69% in inoperable patients and 76% in high-risk
operable patients. Late mortality was primarily the result
of advanced age and debilitating comorbidities such as
severe pulmonary and renal disease (3,4,15). Given the
invasive nature of the procedure and limited resources it
may be as important to decide who will not benefit, as
who will.
Specific Risks of TAVR
Neurological concerns. Stroke is a known potential com-
plication with both SAVR and TAVR (24). For perspective,
the recent European SOURCE (SAPIEN Aortic Biopros-
thesis Multi-Region Outcome Registry) and United King-
dom high-risk TAVR registries reported stroke rates of
2.4% and 4.0%, respectively. The rigorously monitored
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major stroke rate of 4%, arguably justified given the overall
21.9% reduction in death and/or stroke at 2 years (number
needed to treat  4.6) (16).
The PARTNER 1A trial allows direct comparison of
stroke rates between TAVR and SAVR. Major strokes
(strokes with permanent deficit) were similar: 3.8% versus
2.1% at 30 days (p 0.20) (25). As there were relatively few
strokes, an analysis of all neurological events (including
transient ischemic attacks and minor strokes without per-
manent deficit) was performed. Neurological events (with
and without clinical deficit) were increased with TAVR
(5.5% vs. 2.4% at 30 days, p  0.04). Predictors of
eurological events with TAVR included a prior neurolog-
cal event, more severe atherosclerotic burden, worse func-
ional disability, smaller valve area, and transapical access.
Figure 6 The PARTNER 1B Trial Compared Transarterial TAVR
Time to event analyses of death (A), death due to cardiac causes (B), rehosp
Leon MR, Smith CR, Mack M, et al. Transcatheter aortic-valve implantation for
1597–607, with information from Makkar RR, Fontana GP, Jilaihawi H, et al. T
J Med 2012;366:1696–704, with permission from the Massachusetts Medica
catheter aortic valve replacement.he temporal pattern of neurological events was similar for dhe 2 groups, with an increased risk over the first week, but
o subsequent increased hazard over SAVR out beyond 2
ears. At 2-year follow up there was no significant difference
n the overall numbers of strokes with TAVR and SAVR
17). The composite of death and/or stroke with disability
as actually lower (although nonsignificantly) with TAVR
femoral and apical combined) as compared to SAVR
26.5% vs. 28.0% at 1 year, p  0.68) (Fig. 7).
Although data are preliminary, the risk of stroke seems to
e falling with smaller, less traumatic catheters (Fig. 3),
mproved technique, and lower-risk patients (13,24). A
otential role for devices designed to capture or deflect
mbolic material is currently being evaluated (2,21).
ccess concerns. Vascular events have been the most
ommon major complication associated with TAVR and are
ften implicated in procedural mortality. Using the large-
dical Management in Extremely High-Risk (Inoperable) Patients
ion (C), and the combined endpoint of death or stroke (D). Redrawn from
stenosis in patients who cannot undergo surgery. N Engl J Med 2010;363:
theter aortc-valve replacement for inoperable severe aortic stenosis. N Engl
ty. PARTNER  Placement of AoRTic TraNscathetER Valve; TAVR  trans-to Me
italizat
aortic
ransca
l Socieiameter 22-F and 24-F RetroFlex delivery system, the
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studies reported vascular complication rates of 17.9%,
16.2%, and 11.0%, respectively (3,4,18,21). More recent
experience suggests a marked reduction in vascular compli-
cations with lower profile delivery systems, increased expe-
rience, and better vascular screening. As major vascular
injury has been associated with a doubling of procedural
mortality, a favorable impact on survival appears likely.
Surgical access to the femoral artery is giving way to routine
percutaneous access and closure. Moreover, when vascular
complications do occur they are better managed and are less
likely to be associated with mortality. In our own experience
the risk of major vascular complications and major bleeds
has fallen dramatically, into the low single digits (26).
Newer, ultra low–profile systems (down to 14-F) are cur-
rently under evaluation and will likely make transfemoral
Figure 7 The PARTNER 1A 2-Year Outcomes After Transcathet
Kaplan-Meier time-to-event curves are shown for death by intention to treat (A)
and stroke rates were similar. Reprinted from Smith CR, Leon MB, Mack MJ, e
N Engl J Med 2011;364:2187–98, with the permission of the Massachusettstechnically feasible in the majority of patients.Renal concerns. Registry data suggests that a rise in
creatinine following TAVR occurs in 5% to 28% of cases,
albeit generally mild, reversible, and to a lesser degree than
with SAVR (27). Clinical experience suggests that renal
function often improves in response to increased cardiac
output. When renal function does deteriorate this is often a
consequence of hypoperfusion, contrast, and transfusion.
Similarly the randomized PARTNER trials suggested a
reduced need for renal replacement therapy after TAVR as
compared with medical management (1.2% vs. 1.7%) or
SAVR (3.8% vs. 4.6%), although these differences were not
statistically significant.
Coronary concerns. Nonrevascularized coronary artery
disease is common and, when severe, can increase proce-
dural risk. If there is a large ischemic burden percutaneous
revascularization may be desirable. However, clinical expe-
rience suggests that the majority of coronary disease in
Surgical Aortic Valve Replacement
s-treated (B), stroke (C), and the composite of death or stroke (D). Mortality
ranscatheter versus surgical aortic-valve replacement in high-risk patients.
al Society. PARTNER  Placement of AoRTic TraNscathetER Valve.er or
and a
t al. T
Medicelderly patients can be managed conservatively with suffi-
491JACC Vol. 60, No. 6, 2012 Webb and Wood
August 7, 2012:483–92 Transcatheter Aortic Valve Replacementcient reduction in angina accrued from relief of aortic
stenosis alone. TAVR facilitates a strategy of staged revas-
cularization as required.
Acute coronary obstruction may rarely occur, generally
due to displacement of a bulky native valve leaflet over a
coronary ostium (usually the left). Large series suggest a risk
of 0.5% with the SAPIEN valve and a somewhat lower
risk with CoreValve (2,21). When coronary obstruction
does occur successful management may require temporary
cardiopulmonary support and revascularization (28). Factors
that increase the risk of coronary obstruction include an
unusually bulky native leaflet (adjacent to a coronary
ostium), a low origin of the coronary ostium (often
defined as 12 mm from the basal leaflet insertion as
assessed by MDCT), a shallow sinus of Valsalva (offering
less room for the native leaflet), an oversized prosthesis,
and high implantation.
Concomitant mitral regurgitation. Mitral regurgitation is
common in patients with aortic stenosis, increasing both
TAVR and SAVR procedural risk. However, mitral regur-
gitation may be better tolerated following successful AVR
by either modality (29,30). Furthermore mitral regurgita-
tion may sometimes improve following AVR, particularly
when regurgitation is functional. In the PARTNER 1B
trial, 22% of patients had moderate or severe mitral regur-
gitation. Mitral regurgitation was a marker of higher TAVR
procedural mortality, but also of greater procedural benefit
in comparison to medical management. Similarly, in the
PARTNER 1A study, 20% of patients had moderate or
severe mitral regurgitation. Mitral regurgitation was a pre-
dictor of increased procedural mortality; however, this risk
was less with TAVR than SAVR (24.2% vs. 35%) (3). A
therapeutic strategy of replacing the aortic valve alone may
be reasonable in some patients in whom the risk of double
valve surgery might be prohibitive.
The conduction system. The atrioventricular conduction
system passes superficially through the interventricular sep-
tum immediately below the aortic valve. Injury during valve
implantation may result in partial or complete heart block.
Risk factors include advanced age, right bundle branch
block, atrioventricular delay, along with prosthesis over-
sizing and ventricular positioning.
In the PARTNER randomized studies new pacemakers
were no more frequent 1 year following SAPIEN valve
implantation than with medical management (4.5% vs.
7.8%, p  0.27) or with SAVR (5.7% vs. 5.0%, p  0.68)
(3,4). However, CoreValve implantation is more frequently
associated early and late atrioventricular block, presumably
due to greater extension into the left ventricular outflow
tract with compression of the septal conduction tissues. The
requirement for new pacemakers was 3-fold higher follow-
ing CoreValve, as compared with SAPIEN, implantation in
both the United Kingdom and French national registries
(5,6). For this reason routine prophylactic temporary pacing
leads are routinely used, with more prolonged electrocar-
diographic monitoring (31).Failed Surgical Prostheses
Valve-in-valve. Reoperation to replace failed surgical bio-
prostheses may be associated with significant risk. Expe-
rience with implantation of transcatheter valves within
failed bioprostheses has been encouraging (Fig. 8). The
rigid frame of most bioprostheses facilitates THV posi-
tioning and paravalvular sealing, while reducing the risk
of atrioventricular block, annular rupture, and coronary
obstruction. However, some surgical bioprostheses are
radiolucent, stentless, or have externally mounted leaflets
with the potential for coronary ostial obstruction if
diseased bioprosthetic leaflets are in close proximity to
the coronary ostia (32). Small-diameter surgical biopros-
theses (particularly 19 mm) may not allow for optimal
expansion of current transcatheter implants (32–35).
Evidence that valve-in-valve implants are durable re-
mains limited. However, early experience confirms that
TAVR may be a repeatable therapeutic strategy with
important implications (32,34).
Future Directions
Currently, SAVR remains the standard of care for most
patients with symptomatic severe aortic stenosis. However,
transarterial AVR has arguably become the standard of care
for patients for whom surgical risk is prohibitive and an
increasingly reasonable alternative for selected operable
patients in whom the high-risk of either mortality or of
morbidity is “high.” Broader application will require further
Figure 8 Double Valve Replacement
A SAPIEN XT THV (Edwards Lifesciences, Irvine, California) was implanted
inside a stenotic native aortic valve (top left). As a single stage procedure a
second SAPIEN XT (Edwards Lifesciences) (open arrow) was implanted inside a
severely regurgitant surgical mitral bioprostheses (valve-in-valve) (solid arrow).
The patient remains well at 3-year follow up.
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Transcatheter Aortic Valve Replacement August 7, 2012:483–92refinement as well as more rigorous and longer follow-up. It
is possible that, with time, TAVR will become a preferred
option for a much broader group of patients. A major
concern may well be the following: When are patients too
ill, frail, or old to gain significant benefit in terms of
duration or quality of life?
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